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A B S T R A C T
Oncolytic viruses (OVs), viruses that speciﬁcally result in killing tumor cells, represent a promising class of
cancer therapy. Recently, the focus in the OV therapy ﬁeld has shifted from their direct oncolytic eﬀect to their
immune stimulatory eﬀect. OV therapy can function as a “kick start” for the antitumor immune response by
releasing tumor associated antigens and release of inﬂammatory signals. Combining OVs with immune mod-
ulators could enhance the eﬃcacy of both immune and OV therapies. Additionally, genetic engineering of OVs
allows local expression of immune therapeutics, thereby reducing related toxicities. Diﬀerent options to modify
the tumor microenvironment in combination with OV therapy have been explored. The possibilities and ob-
stacles of these combinations will be discussed in this review.
1. Introduction
1.1. The anti-tumor immune response and the immune proﬁle of tumors
The innate and the adaptive immune system work together to detect
transformed cells and remove them before they form a tumor [1]. The
anti-tumor response starts with the release of tumor associated antigens
(TAA) from dying cancer cells and accompanying signal molecules,
which attract and activate cells of the innate immune system [2,3].
Whereas NK and γd-T cells can recognize and kill tumor cells directly,
antigen presenting cells (APCs), such as DCs and macrophages, take up
TAAs to activate the adaptive immune system [4,5]. The maturation of
APCs by the accompanying danger signal molecules determines the
skewing to a preferred T helper cell (Th) 1 response. These Th1 signals
constitute of pro-inﬂammatory cytokines, such as interleukin (IL)-12,
type I interferons (IFNs) and tumor necrosis factor (TNF), and damage-
associated molecular pattern molecules (DAMPs), such as nuclear pro-
tein HMGB1, heat-shock proteins and ATP, [3]. The Th1 cytokines
stimulate the generation of tumor speciﬁc cytotoxic CD8+ T cells
(CTLs), which are crucial eﬀector cells in the antitumor response [6].
Subsequently, eﬀector T cells, including T helper cells and CTLs, are
attracted to the tumor site via a gradient of T cell attracting chemo-
kines, including chemokine (C-C motif) ligand 2 (CCL2), CCL5/
RANTES, chemokine (C-X-C motif) ligand 9 (CXCL9), and CXCL10 [7].
At the site, CTLs recognize and kill tumor cells mediated by MHCI-T cell
receptor interactions. If the immune system succeeds in destruction of
the beginning tumor, the host remains free of cancer.
In some cases, tumor cells are reprogrammed to evade the immune
system resulting in an equilibrium between dying tumor cells and
tumor cells surviving the immune attack. As a consequence, a selection
of immunosuppressive or less immunogenic tumor cell variants is in-
troduced, which cannot be eliminated by the immune system [8]. These
tumor cells establish a tumor microenvironment (TME), in which the
function of anti-tumor immune cells is attenuated (Fig. 1) [9]. First of
all, tumor cells and stromal cells (endothelial and epithelial cells and
ﬁbroblasts) produce factors such as transforming growth factor-β (TGF-
β), prostaglandin E2 (PGE2) and IL-10, that disrupt APC maturation in
the TME [3,7,9]. As a result, DCs isolated from the TME often display a
partly matured, immune suppressive phenotype and secrete cytokines
that induce non-favorable Th2 responses [7]. Secondly, tumors inhibit
inﬁltration of eﬀector T cells by repressing the production of T cell
attracting chemokines CXCL9/10 and modiﬁcation of CCL2 [7,10].
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Thirdly, eﬀector T cells that can inﬁltrate the tumor are attenuated by
expression of several immunosuppressive molecules and persistent ex-
posure to tumor antigens. As a result, T helper cells and CTLs isolated
from the TME often present an exhausted phenotype, characterized by
high level expression of immune checkpoint receptors such as cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell
death protein 1 (PD-1) [10]. Ligation of these receptors with their li-
gands expressed on tumor and stromal cells, but also im-
munosuppressed APCs, leads to inhibition of the tumor speciﬁc T cell
response. Fourthly, regulatory immune cells such as CD4+ regulatory
T cells (Tregs) and myeloid derived suppressor cells (MDSCs) are re-
cruited to the tumor site. Similar to tumor cells, Tregs secrete IL-10,
Indoleamine 2,3-dioxygenase (IDO) and TGF-β, leading to further at-
tenuation of the T cell response [7,11]. Furthermore, Tregs consume IL-
2, which is indispensable for T cell activation [7]. MDSCs contribute to
the suppression of eﬀector T cells through production of arginase and
nitric oxide, which deprives T cells from amino acids necessary for
proliferation [12].
Despite all these evasion mechanisms, CTLs and Th1 T helper cells
are still considered to be the most crucial eﬀector cells in anti-tumor
immunity and their inﬁltration into the TME is associated with good
prognosis in various types of cancer [13]. Proper activation of these
cells is key for an eﬀective antitumor response and the abundance of
mechanisms used by tumors to suppress these cells oﬀers many targets
for cancer immunotherapy strategies.
At the moment, multiple strategies to target the TME are being
explored. Recent successes have led to the FDA approval of checkpoint
inhibitors anti-CTLA-4 (clinical responses in 10–15% of treated pa-
tients) and anti-PD1 (clinical responses in 30–40% of patients) for
treatment of melanoma [14,15]. Clinical trials have shown that dual,
synergistic blockage improved antitumor responses against melanoma,
indicating that it might take more than one approach to induce pow-
erful and long lasting anti-tumor immunity [16,17]. However, systemic
administration of these checkpoint inhibitors, as well as other im-
munotherapies, often coincides with severe immune-related adverse
eﬀects similar to autoimmune diseases [16,17]. A promising treatment
option to potentially overcome this obstacle is oncolytic virotherapy.
1.2. Oncolytic viral therapy
Oncolytic virotherapy is an approach that uses oncolytic viruses
(OVs), either with natural tropism for neoplastic cells or genetically
modiﬁed to enhance selectivity for tumor cells [18,19]. Tumor cells
often lack an adequate antiviral response, making them more suscep-
tible to OV infection than healthy cells. The viral infection leads to
tumor regression through two distinct mechanisms: direct killing of
tumor cells by replication dependent induced cell death and promotion
of an antitumor response towards all tumor cells, including non-in-
fected cells, by inducing immunogenic cell death. Types of im-
munogenic cell death, such as immunogenic apoptosis, necrosis and
autophagic cell death, are characterized by the release of TAAs in
combination with DAMPs and viral pathogen associated molecular
patterns (PAMPs) [19]. Following the secretion of DAMPs and cyto-
kines, more innate immune cells, such as macrophages, DCs, NK cells
and neutrophils inﬁltrate the tumor environment. The immune stimu-
lating cytokine secretion leads to maturation of APCs and hence pre-
sentation of TAAs and viral antigens to activate the adaptive immune
system in the lymph nodes. Cytotoxic T cells will start inﬁltrating the
tumor again and speciﬁcally eliminate cancer cells. Simultaneously,
memory T cells are formed, which improves protection against new
tumor challenges in mouse models [20,21]. Therefore, it is evident that
OV therapy can function as a ‘kick start’ for the antitumor immune
response by providing TAAs in an immunogenic manner and inducing
inﬁltration of immune cells.
Recently, the focus in the oncolytic virotherapy ﬁeld has shifted
from their oncolytic eﬀect to their immune stimulatory eﬀect.
Recombinant OVs armed with immune modulators further enhance the
activation of the immune system and overcome the immunosuppressive
TME [18]. The ﬁrst armed OV approved by the FDA is oncolytic Herpes-
Simplex-Virus (HSV)-1 expressing GM-CSF showing improvement of
Fig. 1. The immunosuppressive tumor micro environment. (A) Tumor
cells (orange) and stromal cells (pink) secrete immune suppressive mole-
cules, which inhibit the maturation of APCs. Maturated APCs migrate to
the lymph node to activate the adaptive immune system. (B) As a result,
activated T cells migrate to the tumor driven by a chemokine gradient.
However, the secretion of chemokines is lowered in the tumor resulting in
reduced T cell inﬁltration. (C) T cells that enter the TME to target the
tumor cells are inhibited by immune suppressive receptors expressed by
the tumor, stromal cell, but also immune suppressed APCs. (D) Tregs and
MDSCs are recruited to the TME, which secrete more immune suppressive
molecules and inhibit the T cell response even further.
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melanoma treatment, but no cure yet (T-VEC) [22]. Therefore, many
more immune modulator armed OV therapies followed and their ob-
stacles and opportunities have come to light. This review will give an
overview of the state-of-the-art therapies used in combination with
immune modulators to treat cancer patients and give a hint on potential
future directions.
2. Immune therapy
Immune therapies for treatment of cancer aim at overcoming the
tumor immune suppressive environment and at increasing antitumor
immunity. Most immune therapies target directly or indirectly the in-
hibitory or stimulatory receptors on immune cells and are often based
on monoclonal antibodies. Other therapies intend to restore the in-
tratumoral balance of cytokines and chemokines into a more favorable
inﬂammatory TME to attract and activate immune cells. The most in-
teresting noncellular therapies for combination with OV therapy for
solid tumors are described below.
2.1. Cytokines
Cytokines are key players in stimulating and regulating antitumor
immune responses. For this reason, one of the ﬁrst immune therapeutic
approaches in cancer treatment was the administration of recombinant
cytokines. As described before, the most essential cytokines in the anti-
tumor response are IL-12, GM-CSF, IL-2 and IL-2-related cytokines IL-15
and IL-21, and they all stimulate diﬀerent parts of the immune system
[23]: GM-CSF recruits APCs to the TME [17], IL-12 is normally ex-
pressed by APCs and stimulates polarization of T helper cells to a Th1
phenotype, IL-2 is a T cell growth factor and improves T cell expansion
[9], and the IL-2-related cytokines promote survival of T cells, but also
play an important role in NK cell activation [23]. Despite the their
plethora of immune modulatory actions, cytokines have lost their po-
pularity as a monotherapy, because of their low objective response rates
and non-negligible side eﬀects upon systemic administration [24,25].
2.2. Inhibitory receptors
One of the most promising immune therapeutics are checkpoint
inhibitors. Inhibitory receptors such as CTLA-4 and PD-1 act as check-
points to avoid over activation and are expressed by T cells and inhibit
the T cell activation in the lymph nodes and survival in the TME [26].
Several checkpoint inhibitors have been approved by the FDA of which
the ﬁrst were against CTLA-4 and PD-1. Treatment with these inhibitors
results in reactivation of the suppressed immune cells [14,15]. In ad-
dition, blocking of CTLA-4 can lead to depletion of Tregs [25]. Com-
binations of a-CTLA-4 antibody and a-PD-1 antibody have shown to
increase responses to treatment of advanced melanoma. However, the
frequency of severe immune-related adverse events was also enhanced
in clinical studies (16.3 −27.3% in monotherapy group vs. 55% in
combination therapy group) [16]. Another disadvantage of these
therapies is the fact that tumors can become resistant towards check-
point inhibitors [27]. As a result, a variety of other co-inhibitory re-
ceptors, such as lymphocyte activation gene 3 (LAG-3) and T cell im-
munoglobulin and mucin receptor protein 3 (TIM-3), have recently
been identiﬁed. LAG-3 is normally activated by its ligand MHCII on
APCs and indirectly reduces T cell proliferation [28]. Interaction of
TIM-3 with its ligand galectin-9, expressed by Tregs, induces cell death
in Th1 cells [28]. Blockage of these inhibitory receptors can unleash
potent antitumor CTL responses and are now in clinical or preclinical
development [17,28].
2.3. Co-stimulatory receptors
Agonistic antibodies are also in development to activate co-stimu-
latory receptors expressed by T cells, such as 4-1BB and OX40 [17].
Stimulation of these two receptors by their ligands or monoclonal an-
tibodies induces activation, proliferation and survival of T cells. An-
other interesting target is CD40, which is expressed on DCs. CD40 li-
gation with CD40L or therapeutic antibody stimulates DC maturation
and presentation of antigens, which leads to eﬃcient T cell priming
[28]. More stimulatory co-receptors are explored today, such as B7.1
and GITR [29–31], which might beneﬁt the eﬀect of current therapies.
2.4. BiTEs
Another class of therapeutics constitute of dual speciﬁcity re-
combinant antibodies, also called bispeciﬁc T cell engagers (BiTEs),
which have shown promise as anti-tumor therapeutics. These anti-
bodies simultaneously bind to CTLs via the T cell receptor (TCR) and a
tumor antigen expressed on the tumor cell resulting in bypassing MHC
dependent antigen presentation [32]. An example of such therapy is
Blinatumomab, which engages the CTL to CD19+ tumor cells. Cur-
rently, it is approved by the FDA for treating acute lymphoblastic leu-
kemia, which is an hematologic malignancy [32].
3. Combination of immune therapy and oncolytic virotherapy
Therapeutic treatment of solid tumors could be enhanced by com-
bination treatment of both immune and OV therapy. By introducing
these discussed immune stimulators, checkpoint inhibitors and cyto-
kines as immune modulators in viral vectors, adverse events can be
reduced, resistance reverted and treatment responsiveness enhanced.
3.1. Combination of OVs with cytokines and chemokines
Several viruses have been engineered to express diﬀerent cytokines
or chemokines. Cytokines and chemokines are attractive transgenes,
because they are encoded by small genes and are in general easy to
build in a viral genome. Moreover, they often have pleiotropic eﬀects,
which means they can target diﬀerent immune cells simultaneously
[23,32]. A complete overview of all cytokines and chemokines used in
oncolytic virotherapy is given in Table 1.
3.1.1. GM-CSF
The most extensively studied transgene is the cytokine GM-CSF.
GM-CSF promotes DC recruitment and maturation. GM-CSF has been
successfully used to arm HSV and this armed virus has been approved
by the FDA under the name of T-VEC for treatment of metastatic mel-
anoma patients [22]. Besides HSV, other viruses have also been armed
with GM-CSF [33,34]. Phase 1 clinical trials in patients with colorectal
and hepatocellular carcinoma, neuroblastoma and Ewings sarcoma
have proven the eﬃcacy and safety of oncolytic vaccinia virus (VV)
expressing GM-CSF (Pexa-Vec) [35–37]. In addition, two diﬀerent
adenovirus serotypes expressing GM-CSF induced long term survival of
patients with, amongst others, ovarian, colon, pancreatic and breast
cancer, with no severe side eﬀects [34,38]. Biopsies obtained from
these patients with diﬀerent metastatic tumors showed increased in-
ﬁltration of T-cells and macrophages, which also correlated with pa-
tient survival and hence the additive eﬀect of GM-CSF as vectorized
immune modulator [38].
3.1.2. IL-12
IL-12 both activates and promotes survival of NK cells, but also Th1
eﬀector cells [39,40]. Several viruses have been armed with IL-12 and
tested in diﬀerent tumor models (Table 1) [41–46]. HSV-IL-12 induces
tumor inﬁltration of eﬀector T cells, NK cells and APCs in neuro-
blastoma and glioma mouse models [43,45]. When comparing HSV-IL-
12 with HSV-GM-CSF, HSV-IL-12 was demonstrated most eﬀective in
tumor growth inhibition of injected tumors as well as metastases in a
squamous cell carcinoma mouse model and a prostate cancer mouse
model [47,48]. In addition, mice were better protected against re-
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Table 1
Combination therapy of armed oncolytic viruses and immune modulators.
Transgene Virus Tumor Additive immunologic eﬀects Toxicity
Cytokines
GM-CSF HSV [22,48,121] Adenocarcinoma [33], Metastised (phase I)a
[22,34] Breast cancer [121], Melanoma
(phase I)a [121,122]
Improved peripheral blood mononuclear
cell response [124]
Grade 1 and 2
[22,34],
AdV [34,110,122] CD3+ T cell inﬁltration [33]
MV [33] Long-term immunity against rechallenge
with tumor cells [33]
VSV [123]
NDV [124]
IL-12 AdV [108] Neuroblastoma [45], Glioma [43], Prostate
[48], Squamous Cell Carcinoma [46,47],
Melanoma [108]
Inﬁltration of macrophages, T helper,
CTL and NK cells [43,45,47,48]
No signs [44,46,47]
HSV [30,43–45,47,48] Improved survival [108] and protective
against rechallenge [47]
VSV [46]
IL-2 NDV [52–56] Melanoma [54,55], Hepatoma [52,53],
Squamous Cell Carcinoma [51]
Inﬁltration of T helper and CTL [51–56] No signs [53,54]
HSV [51] Immunity against rechallenge with
tumor cells [51–54]
IL-15 VSV [57] Colon carcinoma [57], Melanoma [58,127] Increase in tumor speciﬁc CTLs in the
blood [57]
IL-15 only detectable
in tumor [58]
NDV [58] Inﬁltration of T helper and CTL [58],
[126]
IAV [125] Immunity against rechallenge with
tumor cells [58]
HSV [126] Increases survival in mouse model
[58,127]
IAV [127]
IFN-β MV [61] Non-small cell lung cancer [128], [129], Improved survival mouse model [61] Not reported
VV [128] Mesothelioma [61], Pancreatic
adenocarcinoma [59]
VSV [129]
NDV [59]
IFN-γ NDV [55] Melanoma [55], Mammary and colon
carcinoma[62]
Increased cytokine expression and
improved DC maturation [62]
Not Reported
VSV [62] Increased T cell inﬁltration [55]
Others: IL-18[30], [108], IL-
17[130], TNF[55], MIP1a[131],
FLT3L[131]
NDV [55] Improved T cell responses Not reported
VSV [130]
AdV [108]
HSV [30]
Chemokines: CCL5[65], CCL2[67],
CCL19[132], CXCL11[64],
[133]
VV [65,66,122,123] Colon carcinoma Improved DC maturation [65] Not reported
HSV [67] Improved inﬁltration T helper cells and
CTLs [64], [65], [132], [133]
Induces a Th2 response, but reverts to a
Th1 response in combination with DC
vaccination [65]
Co-stimulatory ligands
B7.1/CD80 HSV [84] Neuroblastoma[84], Melanoma (patients)a
[86]
Immunity against rechallenge with
tumor cells [84]
Low grade [86]
VV [86] Response in 3/11 patients [86]
4-1BBL/CD137L VV [89] Melanoma No diﬀerence in DC maturation Not reported
Inﬁltration of CTL
CD40L AdV [92] Melanoma[93], More Th1 cytokines [92] No signs [92]
AdVdd [90] Solid tumor (patients)a[92] Inﬁltration of T helper, CTL, NK, DC,
MDSC [93]
VV [93] Improved survival, but not with armed
VSV [90]
VSV [90]
OX-40L AdV [95] Melanoma, lung carcinoma Inﬁltration of T helper and CTL Not reported
GITRL AdV [31] Melanoma Inﬁltration of T helper and CTL No signs
LIGHT AdV [99] Prostate Recruitment of eﬀector T cells
Reduced Treg suppression
Not reported
CD70 VV [98] Colon adenocarcinoma Reduced tumor growth Not reported
Checkpoint inhibitors
anti-CTLA4 MV [75] Melanoma Inﬁltration of T helper and CTL [75],
[108]
No signs [75], [108]
AdV [74,108] Decreased inﬁltration of Tregs [75]
anti-PD1 or PD-L1 MV [75] Melanoma Inﬁltration of T helper and CTL [75],
[83]
No signs [75]
VV [83] Decreased inﬁltration of Tregs [75],
[83]
MYXV [81] Improved survival [81]
(continued on next page)
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challenges with tumor cells in the HSV-IL-12 treated group, indicating
the formation of a long term, anti-tumor response [47]. Similarly,
adenovirus armed with IL-12 showed improved tumor reduction com-
pared to adenovirus armed with GM-CSF in a thyroid cancer rat model
[49]. In conclusion, multiple studies demonstrate that OVs armed with
IL-12 yield better anti-tumor eﬀects than vectorized GM-CSF and can
even be further improved by combining diﬀerent immune modulators.
3.1.3. IL-2 and IL-15
IL-2 and IL-15 both signal via cytokine receptors of the common γ
chain family and are important for the stimulation, proliferation and
survival of T cells and NK cells [23,50]. Systemic treatment with IL-2 is
associated with major adverse side eﬀects in humans [24]. Therefore,
local delivery of IL-2 by OVs has been tested by several research groups
[51–56]. In these murine studies, reduced tumor growth and increased
T cell inﬁltration of the tumors was reported. No distress was observed
in mice and IL-2 production was limited to the tumor site, which might
indicate less side-eﬀects when administrated to humans [53–55]. Also,
mice were protected from re-challenge with tumor cells suggesting in-
duction of long term tumor speciﬁc immunity and thus show promise as
vectorized immune modulator [52–55].
Despite the promising eﬀects of IL-2, IL-15 showed to have several
advantages over IL-2. In contrast to IL-2, Il-15 can stimulate only NK
and eﬀector T-cells, whereas IL-2 has also the undesirable eﬀect of
stimulating Tregs [50]. Even though systemic treatment with IL-15
induces less toxic eﬀects local expression of IL-15 mediated by armed
Vescilular Stomatitus virus (VSV) enhanced anti-tumor activity com-
pared to VSV treatment combined with systemic IL-15 in murine
models [57]. Vectorization by NDV demonstrated that IL-15 induced
more CTL inﬁltration and increased activation of tumor-speciﬁc eﬀector
cells resulting in improved survival rates compared to IL-2 in a mela-
noma mouse model [58]. Altogether, these studies indicate that treat-
ment with OVs expressing IL-15 is more eﬃcient than systemic treat-
ment with IL-15 or treatment with OVs expressing IL-2.
3.1.4. Type I and II interferons
IFN-α/β are important in antiviral responses, but also play a role in
anti-cancer immunity by inducing DC maturation and CTL and NK cell
activation [23,32]. In addition, they result in upregulation of MHC I
expression on tumor cells and can have direct eﬀect on cell prolifera-
tion. Only a few studies have investigated OVs armed with type I in-
terferons [59–61]. The direct anti-tumor eﬀects of IFN-β expressed by
the measles virus (MV) and NDV has been demonstrated in immune
deﬁcient mouse models leading to some improvement of the viral
therapy. Buijs et al. showed that a virus expressing IFN-β interfered
with oncolytic NDV replication, whereas Willmon et al. and Li et al.
found that viral IFN-β expression did not interfere with VSV and MV
replication [59–61]. However, the immune stimulating eﬀect of virus
mediated IFN-β expression still needs to be assessed in an im-
munocompetent model to determine the potency of IFN-β as transgene.
Type II interferon (IFN-γ) is an important Th1 eﬀector cytokine,
secreted by activated Th1 cells, CTLs and NK cells [23]. IFN-γ upre-
gulates MHC I expression in tumor cells and promotes Th1 skewing via
an autocrine loop [23]. A recent study describing VSV expressing IFN-γ
suggested that this virus induces a stronger immune response by in-
creasing MHC I antigen presentation on tumor cells, enhancing DC
maturation and attracting T cells to the tumor site by inducing CCL2
expression in mice [62]. The authors did not observe any diﬀerence in
viral replication, even though IFN-γ is also known for its antiviral ac-
tivity. In another murine study, treatment with NDV- IFN-γ did not
result in a signiﬁcant beneﬁcial eﬀect compared to unarmed NDV [55].
In conclusion, arming OVs with IFN-γ has been shown to be eﬀective,
but eﬃcacy may depend on the virus used.
3.1.5. Eﬀector cell attracting chemokines
Insuﬃcient inﬁltration of eﬀector lymphocytes in the tumor often
correlates with low eﬃcacy of T cell stimulating immunotherapies
[7,10]. Therefore, OVs armed with chemokines, which attract eﬀector
cells, may improve antitumor eﬃcacy in addition to the endogenous
chemokine release upon viral infection. Important chemokines in the
TME are CCL2, CCL5 (RANTES), CXCL9 and CXCL10, which attract Th1
Table 1 (continued)
Transgene Virus Tumor Additive immunologic eﬀects Toxicity
Combinations
GM-CSF+IL-12 AdV [104,105] Melanoma Secreted cytokine proﬁle shifted from
Th2 to Th2 response [105]
Not reported
Inﬁltration of T helper, CTL, NK and DC
[104], [105]
Immunity against rechallenge with
tumor cells [105]
IL-12+ IL-18 AdV [106] Melanoma Inﬁltration of T helper, CTL, NK Not reported
IL-12+CCL2 HSV [67] Neuroblastoma Reduced tumor growth Not reported
B7.1+ IL-12 AdV [41] Melanoma Inﬁltration of T helper, CTL and DC Not reported
B7.1+ IL-18 HSV [132] Neuroblastoma, Prostate Reduced tumor growth
No signiﬁcant diﬀerence in survival
Not reported
B7.1+GM-CSF AdV [85] Melanoma Inﬁltration of T helper, CTL and DC
Immunity against rechallenge with
tumor cell
Not reported
4-1BBL+ IL-12 AdV [42] Melanoma Inﬁltration DC, T helper and CTL No signs
Others
HPGD VV [100] Several tumor models Expression of Th1 cytokines, CXCL10/
11, CCL5
Not reported
Decreased inﬁltration MDSC
More DCs secreting IL-12 in LN
TRIF VV [100] Renal cell carcinoma Increased immune stimulatory cytokine
response
Not reported
Improved survival
DAI VV [103] Melanoma Improved CD8+ cell inﬁltration Not reported
Reduced tumor growth
a indicates patient studies, whereas other studies were performed in mouse models.
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cells and CTLs and CCL22, which attracts undesirable Tregs [63].
Combination of OV therapy with a chemokine modulating cocktail,
which induces production of CCL5 and CXCL10 while reducing CCL22,
was shown to promote traﬃcking of T helper cells and CTLs to the TME
and resulted in improved survival in a murine colon cancer model [64].
Administration of viruses armed with CCL5 or CCL2 both resulted in
increased numbers of inﬁltrating Th1 cells in colon cancer and neuro-
blastoma [65–67]. In conclusion, these studies have shown that the use
of OVs armed with chemokines eﬃciently increased the inﬁltration of T
cells into the tumor. However, none of the studies have assessed the
inﬁltration of immune cells in distant tumors and tumor reduction has
not been mentioned.
3.2. Combination of OVs with blocking of co-inhibitory receptors
The most popular immunotherapeutics are the checkpoint in-
hibitors, anti-CTLA-4 or anti-PD-1/PD-L1, yielding promising eﬀects
but coinciding with major adverse eﬀects, as described above [68]. In
addition, some tumors are resistant to these immunotherapies, depen-
dent on the immunogenicity of the tumor and the suppression of the
anti-tumor immune responses in the TME [69]. Combination of sys-
temic immunotherapeutics with localized OV therapy may enhance
their therapeutic eﬃcacy and may overcome tumor resistance and re-
duce immune related adverse eﬀects.
3.2.1. CTLA-4
CTLA-4 is a checkpoint inhibitor that inhibits early stages of T cell
activation in the lymph nodes, but also stimulates undesirable Treg
functions [28,68]. Blockage of CTLA-4 signaling releases a brake on T
cell activation and even depletes intratumoral Tregs [28]. Intratumoral
administration of NDV combined with systemic treatment with anti-
CTLA-4 (Ipilimumab) showed improved antitumor eﬀect mediated by
CTLs and NK cells in a murine melanoma model [70]. Studies using
combinations of systemic CTLA-4 blockade with other OVs (VV [71,72]
and VSV [20]) showed prolonged survival in renal [71], lung [72] and
mammary [20] tumor models, long term protection to re-challenge
with tumor cells [71,72], and even cured mice [20]. Moreover, T-VEC
combined with systemic CTLA-4 blockade has been evaluated for
therapy in melanoma patients, which yielded a tumor growth control
that was signiﬁcantly greater than observed after both monotherapies
[73]. The incidence of severe adverse eﬀects was similar to Ipilimumab
monotherapy [68], [73]. Local expression of anti-CTLA-4 induced by
administration of adenovirus armed with anti-CTLA-4 resulted in sig-
niﬁcantly higher concentrations of the antibody in the treated tumor,
while plasma levels remained at concentrations indicated as safe in
murine models [74]. However, Engeland et al. demonstrated that
treatment with MV armed with anti-CTLA-4 was less eﬃcient than in-
tratumoral treatment with MV combined with systemic administration
of anti-CTLA-4, presumably because the major site of action of CTLA-4
is in the lymph node and not in the periphery [75]. Though local ex-
pression may lead to transient expression of the transgene in tumor
draining lymph nodes, this study indicated that systemic anti-CTLA-4
therapy may be required for optimal responses.
3.2.2. PD-1 and PD-L1
With a completely diﬀerent mechanism of action, PD-1 is also a
checkpoint inhibitor expressed by eﬀector T cells [68]. While CTLA-4
inhibits T cells in early activation stages in the lymph nodes, PD-1
signaling limits the function of activated T cells at later stages of the
immune response taking place in tumors and tissues [68]. Multiple OVs
such as MV [76], reovirus [77,78], and VSV [79,80], have been com-
bined with systemic PD-1 blockade in treatment of murine glioblastoma
[76], melanoma [77,78], and acute myeloid leukemia [79] tumor
models, resulting in enhanced inﬂux of CTLs in the tumors and pro-
longed survival in mice. Speciﬁcally CTLs and NK cells, but not T helper
cells, were shown to mediate the beneﬁcial eﬀects [77,79,81].
Moreover, a phase 1b clinical trial with the FDA approved T-VEC
combined with PD-1 resulted in good response rates in patients [82].
Arming Myxoma Virus (MYXV) with anti-PD-1 did result in improved
survival in mice as well [81]. However, local expression induced by
administration of MV or VV armed with anti-PD-1 or anti-PD-L1 de-
monstrated to be as eﬃcient as therapy with unarmed VV combined
with systemic anti-PD-1/anti-PD-L1 treatment in murine tumor models
[75,83]. In conclusion, these studies suggest that OVs combined with
checkpoint inhibitors improve treatment, but the beneﬁts of vector-
ization diﬀer per oncolytic virus.
3.3. Combination of OVs with activation of co-stimulatory receptors
3.3.1. B7-1
B7-1 (CD80) is expressed by APCs and a potent co-stimulatory
molecule for T cells. B7-1 provides co-stimulation via interaction with
CD28 on T cells, but inhibits T cells through interaction with CTLA-4
[28]. Nevertheless, several OVs armed with B7-1 have been tested in
(pre)- clinical trials for the treatment of melanoma [41,84–86]. Re-
plication defective HSV expressing soluble B7-1 induced a prolonged
tumor speciﬁc immune response in mice bearing neuroblastoma tumors
[84]. VV expressing B7-1 was eventually evaluated in melanoma pa-
tients, where the treatment was well tolerated, but only few patients
responded [86]. Overall, OV expression of B7-1 seems to have addi-
tional beneﬁts in combination with other transgenes, but not as a single
transgene.
3.3.2. 4-1BB
4-1BB is a surface protein primarily present on activated T cells and
NK cells. 4-1BB signaling promotes Th1 skewing over Th2, protects T
cells from activation induced cell death and enhances cytotoxic activity
of T cells and NK cells [28]. 4-1BB signaling has been shown to be more
potent in T cell activation compared to the CD28 co-stimulation by B7-1
[87]. A combination of oncolytic VV with systemic anti-4-1BB admin-
istration in a breast cancer model resulted in increased survival and
tumor inﬁltration by CTLs compared to both monotherapies in patients
(40% survival vs. 0% survival) [88]. Local expression of 4-1BB ligand
(4-1BBL) by oncolytic VV in mice has demonstrated to enhance tumor
regression and this eﬀect was enhanced even more in combination with
lymph node depletion in order to slow down viral clearance [89]. Local
injection of the armed virus resulted in an improved CTL/Treg ratio in
the TME. In another study, vectorization of both IL-12 and 4-1BBL by
adenovirus increased T helper, CTL and DC inﬁltration, which resulted
in improved survival of the mice [42]. In other murine models, DC
vaccination combined with the armed adenovirus combined treatment
yielded even better results and DCs showed enhanced migration to the
tumor draining lymph node, where they activated T cells [42]. These
studies have shown that vectorization of this immune modulator in OVs
enhances its therapeutic eﬃcacy.
3.3.3. CD40
The maturation and activation status of DCs is often a limiting factor
in the induction of antitumor immune responses. Ligation of the CD40
receptor provides a strong activating signal to DCs, resulting in upre-
gulation of MHC II and co-stimulatory molecules and production of IL-
12, which is important for skewing of T cells towards a Th1 phenotype
[28]. As DC activation takes place in the TME, treatment with OVs
armed with a stimulatory CD40 antibody or CD40 ligand (CD40L) may
lead to enhanced therapeutic eﬃcacy.
Adenoviruses armed with CD40L have been tested in melanoma
mouse models and patients with diﬀerent types of cancer [90–92].
Treatment with a CD40L expressing VV resulted in tumor growth in-
hibition and increased inﬁltration of eﬀector T cells, NK cells, DCs in a
melanoma mouse model. However, also numbers of Myeloid derived
suppressor cells increased of which its eﬀects are unknown [93]. When
evaluated in a clinical trial, patients showed disease control for 3–6
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months and a systemic tumor speciﬁc immune response was induced
[92].
3.3.4. OX40
Similar to checkpoint inhibitors, more and more co-stimulatory
targets, such as OX40 and GITR, are being discovered as anti-tumor
targets. The OX40 receptor is expressed by activated T cells and induces
the production of Th1 and Th2 cytokines upon interaction with OX40
ligand (OX40L) [28,94]. OX40 ligation also directly blunts the sup-
pressive eﬀects of Tregs [28,94]. Arming of OV with OX40L has been
described once: adenovirus expressing OX40L led to suppression of
melanoma, lung and colon tumor growth in mice. This eﬀect was
mediated by Th1 cells and CTLs and an increase in Th1 rather than Th2
cytokine expression [95]. A study combining systemic OX40L therapy
with systemic 4-1BBL therapy and IL-12 expressing adenovirus, re-
vealed increased expression of Th1 cytokines. thereby the antitumor
CTL response were enhanced leading to tumor rejection in a colorectal
cancer model involving liver metastases compared to OX40L mono-
therapy and combined 4-1BBL and IL-12 armed OV treatment [96]. This
makes OX40 an interesting transgene, but more research needs to be
performed to elucidate its beneﬁcial eﬀects in other tumor models and
OVs.
3.3.5. GITR
GITR is a stimulatory receptor expressed on activated T cells, but it
is also constitutively expressed on Tregs [28,94]. Activation of the re-
ceptor promotes proliferation and cytokine production in T eﬀector
cells, whereas it inhibits Tregs [28,94]. Expression of GITR ligand itself
by an adenoviral vector resulted in increased inﬁltration of T helper
cells and CTLs and suppression of tumor growth, leading to prolonged
survival [31]. Systemic administration of a stimulating GITR antibody
together with intratumoral injection of an adenoviral vector armed with
IFN-α resulted in enhanced tumor growth inhibition in injected and
distant tumors compared to single treatment in colon and pancreatic
murine cancer models [97]. This makes GITR ligand attractive as a
transgene, but similar to OX40L, more research needs to be performed.
More research needs to be done towards these targets, just like for the
newly discovered LIGHT and CD27 anti-tumor targets [98,99],
(Table 1).
3.4. Combination of OVs with other immune stimulatory approaches
3.4.1. Prostaglandin E2 blockade
Prostaglandin E2 (PGE2) is a principal mediator of inﬂammation
expressed by tumor cells and immune cells and stimulates accumulation
of MDSCs in the TME. Moreover, PGE2 induces IDO and IL-10 expres-
sion in DCs, whereas it reduces IL-12 expression, which is necessary to
induce a Th1 response [7,10]. A recent study, revealed PGE2 as an
important mediator of resistance to OV therapy and other im-
munotherapies [100]. Treatment of mice with VV expressing a PGE2
inactivating enzyme named hydroxyprostaglandin dehydrogenase
(HPGD), resulted in a decreased number of MDSCs in the tumor and
yielded a better response than other PGE2 blocking agents [100]. The
virus was also shown to sensitize an otherwise resistant renal tumor to
anti-PD-1 treatment [100]. Thus, blockade of PGE2 showed promising
results but this approach needs further validation in other tumor
models and with other OVs.
3.4.2. Pathogen receptors
Toll like receptors (TLRs) are part of the innate immune system and
recognize pathogenic molecules such as bacterial lipids and proteins or
viral DNA and RNA [101]. The type of TLR that is activated upon in-
fection is an important determinant for the skewing of the subsequent
adaptive immune response [101]. Manipulation of TLR signaling can
therefore switch the induced immune response from Th2 to Th1.
TRIF mediates TLR3 signaling, whereas other TLRs signal via
MyD88 [101]. Moreover, this pathway induces the production of Th1
cytokines instead of Th2 cytokines. To manipulate TLR3 signaling, a VV
was engineered to express TRIF to increase TLR3 signaling [102]. In
addition, the viral particle was deglycosylated, resulting in reduced Th2
responses. Treatment of mice with deglycosylated VV-TRIF resulted in
increased production of Th1 but not Th2 cytokines in the TME. Also, the
virus induced inﬁltration of T helper cells and CTLs. These CTLs were
both virus and tumor cell speciﬁc. VV-TRIF showed improved anti-
tumor eﬃcacy in colon and renal tumor models compared to VV-GM-
CSF (Pexa-Vec). Similar results were obtained using intracellular pat-
tern recognition receptor DNA-dependent activator of IFN-regulatory
factors (DAI) as an vectorized immune modulator [103]. These studies
show that the antitumor immune response can be switched from Th2 to
Th1 by manipulating intracellular pathogen receptor signaling path-
ways in tumor cells.
3.4.3. BiTEs
BiTEs (bispeciﬁc T cell engagers) are a class of bispeciﬁc mono-
clonal antibodies that have shown promising anti-tumor eﬀects [104].
However, they have a very short half-life and therefore require con-
tinuous infusion. Vaccinia virus (VV) armed with a BiTE with speciﬁcity
for the TCR and a TAA was tested in a xenograft lung cancer mouse
model. The study showed increased tumor cell killing through T cell
activation and skewing towards Th1 responses [105]. A disadvantage of
BiTEs is that they target only one TAA and therefore stimulate the
immune response directed to only that TAA, while other immune-
modulatory transgenes induce immunity to multiple TAAs that are re-
leased by dying tumor cells.
3.5. Combining diﬀerent immune modulators
To further improve the eﬃcacy of OV treatment, diﬀerent combi-
nations of therapies are being exploited. OVs armed with several cy-
tokine combinations have been tested with promising results.
Adenovirus expressing both GM-CSF and IL-12 induced inﬁltration of
eﬀector T cells, NK cells and activated APCs combined with DC vacci-
nation in a melanoma mouse model, as well as long-term protection to
re-challenge with tumor cells [106]. Moreover, viral expression of GM-
CSF and IL-12 in the TME shifted the intratumoral cytokine proﬁle from
a Th2 to a preferred Th1 response and improved DC migration to the
tumor site [106,107]. Similarly, viral co-expression of IL-12 and IL-18
showed enhanced therapeutic eﬃcacy and increased inﬁltration of DCs
and eﬀector T cells compared to mono-expression of IL-12 in murine
models [41,42,108]. The combination of IL-12 and IL-18 showed to
have synergistic eﬀects on IFN-γ production, an important Th1 eﬀector
cytokine, by T cells and NK cells and polarization towards a Th1 re-
sponse [28,109]. Combining IL-12 expression with CCL2, an important
T-cell chemokine, resulted in enhanced neuroblastoma growth inhibi-
tion compared to administration of armed HSV alone demonstrating the
potential of combining diﬀerent cytokines and chemokines in mice
[67].
In addition, cytokines have also been combined with immune sti-
mulatory receptor ligands. Treatment with adenovirus armed with GM-
CSF and B7-1 in a melanoma mouse model resulted in prolonged sur-
vival and resistance to tumor re-challenge compared to treatment with
unarmed adenovirus [85]. Similarly, treatment with oncolytic adeno-
virus armed with IL-12 as well as B7-1 resulted more often in complete
regression in a melanoma mouse model compared to adenovirus armed
with IL-12 alone [41]. Combination of three armed OVs with IL-12, IL-
18, and B7-1 yielded signiﬁcant better results in inhibition of local and
distant tumor growth in a neuroblastoma mouse model, compared to
single vector treatment demonstrating the possible synergistic eﬀects
between cytokines and co-stimulatory receptors [30].
The combination of checkpoint inhibitors and cytokines work
equally well. Co-administration of oncolytic adenovirus expressing GM-
CSF and oncolytic adenovirus expressing anti-CTLA-4 has been shown
J.F. de Graaf et al. Cytokine and Growth Factor Reviews xxx (xxxx) xxx–xxx
7
to yield additive antitumor activity in a lung cancer mouse model
[110]. Furthermore, T-VEC in combination with systemic treatment
with anti-CTLA-4 resulted in signiﬁcantly improved tumor growth
control rates in patients with advanced melanoma compared to both
monotherapies alone [73]. Currently T-VEC in combination with anti-
PD-1 is being evaluated in clinical trials [111], but the results are still
unknown. In addition, Sorensen et al. engineered a replication deﬁcient
adenovirus expressing a TAA. By combining administration of this virus
with systemic administration of CD40 stimulatory antibodies and CTLA-
4 blockage, tumor growth of melanoma was reduced and long term
survival was observed in 30–40% of mice in contrast to the mono-
therapies [112]. Thus, stimulation of both DCs and T cells is necessary
for long term anti-tumor immune response. Therefore, these (pre-)
clinical trials with combination-therapies demonstrate the potential to
improve current therapies.
Taken together, these studies provide a strong rationale for further
evaluation of OVs as a local delivery vector for immunotherapies tar-
geting co-stimulatory and co-inhibitory receptors on anti-tumor eﬀector
cells or other parts of the TME.
4. Discussion and future directions
OVs represent a class of promising agents to treat cancer. Besides
their direct oncolytic eﬀects, they can function as a ‘kick-start’ for anti-
tumor immunity. Combining OV therapy with existing immune thera-
pies enhances the potential of both therapies by synergizing their ef-
fects. Many diﬀerent combinations have been tested and are summar-
ized in this review (Table 1). These studies have broadened our
understanding of the strengths of OV immune therapies, but also of its
limitations. As a result, these learning lessons enable us to discuss the
potential future directions and further considerations in deciding on
eﬀective immune modulators and viral combinations and reducing
risks.
4.1. Eﬀective immune modulators
One of the greatest advantages of OVs armed with immune mod-
ulators is that this therapy often induces safer systemic and/or more
eﬀective localized concentrations of the modulator than systemic
monotherapy [58,86,92]. Nevertheless, vectorization of checkpoint
inhibitors can also limit the potency of the immune therapies by in-
correct localization and timing and no resilience in case of tumor re-
sistance. With regard to localization, a checkpoint receptor, such as
CTLA-4, is mainly functional in the lymph node and requires systemic
delivery of the blocking antibodies [72]. For instance, the anti-CTLA-4
armed MV proved to be less eﬀective than monotherapy with CTLA-4
inhibitors [75]. Similar results were found for PD-L1 inhibitors deliv-
ered by MV and VV [75,83], illustrating the second disadvantage of
OVs armed with checkpoint inhibitors: the timing of administration of
combined therapies. Rojas et al. and Gao et al. demonstrated that sys-
temic administration of immune therapeutics given shortly (1–3 days)
after OV therapy resulted in additive eﬃcacy of the combination
therapy in contrast to immune therapeutics given prior to OV admin-
istration [71,113]. However, timing strategies may diﬀer per virus as
was seen with the armed MYXV where vectorization of anti-PD-1 did
result in additive eﬀects [81]. In addition to localization and timing,
multiple studies have shown the development of resistance towards
these checkpoint inhibitors over time in which new inhibitory mole-
cules were upregulated on the cancer cells rendering the therapy in-
eﬀective [27]. Systemic administration of checkpoint inhibitors would
allow for an easier transition between checkpoint therapies if necessary.
Therefore, we think that arming viruses with checkpoint inhibitors
might not be the most eﬀective combination strategy.
An alternative approach to consider would be the targeting of APCs,
NK cells and CTLs by arming viruses with immune stimulating agonists
and cytokines. These immune cells express a known and stable subset of
cytokine and co-stimulatory receptors and hence circumvent the
treatment resistance as is seen with checkpoint inhibitors. Several stu-
dies have shown the additive eﬀects of OVs armed with these agonistic
agents compared to OV therapy alone (Table 1). In addition, the loca-
lized expression of agonistic agents reduces adverse eﬀects in contrast
to systemic administration and still allow combination therapy with
checkpoint inhibitors [58,114,115]. Based on the reviewed studies, we
reason that both cytokines and agonists targeting co-stimulatory re-
ceptors are very promising as immune modulators in the OV treatment
against solid tumors.
4.2. Viral combinations
Another point of consideration is the combination of the virus and
the immune modulator. The virus determines both the ‘kick-start’ ef-
fect, which initiates the inﬂammation, and the concentration and
duration of expression of the vectorized immune modulators. However,
viruses diﬀer in the eﬀectiveness in killing the target cell or in ex-
pressing the immune modulator. For example, in a study comparing
VSV with a replication defective adeno virus, both expressing CD40L, it
was shown that the replication defective virus was superior in in-
creasing survival rates over the replicative virus [116]. This is probably
because of the low immunogenicity of the replication defective virus
resulting in reduced viral clearance by the immune system and hence
more immune modulator secretion. However, whether the beneﬁts of a
weaker immune response hold true for all therapies remains unknown
and probably depends on the virus.
In addition to oncolytic activity, the eﬃcacy of the OV immune
therapy is inﬂuenced by the eﬃciency of a virus to express the immune
modulators. For instance, for NDV it has been shown that the insertion
site in the virus determines the expression levels of the transgene [56].
The eﬀect of the insertion site may also hold true for other OVs, but is
often not discussed. In addition, the size of the immune modulators is
also of importance. Studies using a complete monoclonal antibody, only
the light chain or a single-chain variable fragment showed that smaller
proteins were more eﬀectively produced than the larger proteins by
cells infected with VV. However, the single chain fragment without an
IgG domain was degraded faster in the TME, resulting in similar anti-
tumor activity as the monoclonal antibody [83]. As not all viruses
tolerate large insertions, this information should be considered when
deciding which modulator to incorporate. However, predicting the ef-
ﬁciency of the modulator expression remains diﬃcult, because diﬀer-
ences in expression levels can occur between tumors independent of the
virus [110].
4.3. Reducing risks
While moving forward with OV immune therapies to the clinic,
safety ought to be considered once more. So far, no adverse eﬀects have
been reported on the therapies combining OV with immune therapies in
murine models or clinical trials. Nevertheless, adverse eﬀects of the
viral infection, such as excessive viral replication or expression of the
immune modulators leading to an overreaction of the immune system
cannot be excluded yet. A possibility to reduce the risks on adverse
eﬀects would be the incorporation of a fail-safe mechanism into the OV
therapy to abort viral replication if necessary. Only for HSV, drugs are
available to inhibit viral replication [117]. Alternatively, virus with
attenuated virulence or viruses with a diﬀerent host range may be used.
In addition, incorporation of suicide genes, such as thymidine kinase
[117], rat cytochrome P450 [118] or cytosine deaminase [119], would
allow inhibition of viral replication by using drugs as well. Moreover, it
could add to the tumor lytic eﬃcacy of the therapy [120]. During OV
therapy, the immune modulator is not incorporated into the host
genome and therefore expression levels are dependent on viral re-
plication which is usually transient. Thus, controlling the viral re-
plication would reduce the risks on severe adverse eﬀects of the
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immune modulators.
In conclusion, the overall eﬀect of the oncolytic immune therapy
depends on the interplay between virus, immune modulator and tumor.
Not only tumors develop over time, but the immune system as well.
This means that every stage of immune activation should be considered
while deciding on the incorporation of an immune modulator (Fig. 2).
Weak immunogenic tumors in an immunosuppressive TME will likely
beneﬁt from potent oncolytic viruses, cytokines and innate stimulating
agonists to activate the initial innate immune response. If eventually
the tumor is inﬂamed, eﬀector T cells and NK cells responses can be
improved by immune activating agonists, such as 4-1BBL, and check-
point inhibitors. The vectorization of both cytokines and immune ac-
tivating agonists could reduce possible adverse eﬀects compared to
systemic administration, whereas systemic delivery of checkpoint in-
hibitors improves the timing and localization of the treatment. Future
directions will have to explore multiple combinations of dually armed
OVs allowing to overcome tumor heterogeneity or at least to use both
OVs and immune modulators to their full potential.
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